Forskolin, a known adenylyl cyclase stimulator, raises cyclic AMP levels, triggering protein kinase A into action, which in turn phosphorylates target proteins, potentially including EF-CAB5. IBMX, another agent that boosts cAMP and cGMP concentrations, works by inhibiting the enzymes that degrade these cyclic nucleotides, leading to amplified signaling through kinases like PKA and PKG, pathways that can intersect with EF-CAB5's activation. Calcium ion flux is a pivotal player in the activation of EF-CAB5. Ionomycin, a calcium ionophore, directly increases intracellular calcium, which then stimulates calmodulin-dependent kinases capable of modifying proteins through phosphorylation, a possible route to EF-CAB5's activation. PMA, a diacylglycerol analog, activates protein kinase C, inducing phosphorylation events with potential repercussions for EF-CAB5. The phospholipase C pathway, perturbed by U73122, results in altered diacylglycerol and inositol triphosphate levels, with a cascade effect that may impinge upon EF-CAB5's state.
Inhibitors like LY294002 and PD98059 reshape the intracellular signaling landscape by targeting PI3K and MEK, respectively. These disruptions in signaling can lead to a reconfiguration of EF-CAB5 activation due to changes in downstream targets. AICAR, by activating AMPK, influences various metabolic and stress-related signals that are likely to impact EF-CAB5's activity. The modulation of the p38 MAPK pathway by SB203580 and the JNK pathway by SP600125 lead to alterations in transcription factor activities and cellular responses, which are probable avenues for EF-CAB5 activation. Furthermore, okadaic acid's inhibition of protein phosphatases such as PP1 and PP2A ensures that phosphorylated proteins remain so, thereby skewing the cellular environment towards a state that supports EF-CAB5 activation. Thapsigargin, by impeding the function of the SERCA pump, causes a rise in cytosolic calcium levels, again favoring conditions that activate calcium-responsive kinases and possibly EF-CAB5.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Elevates cAMP levels, which can activate PKA, leading to phosphorylation events that activate EF-CAB5. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Non-specific phosphodiesterase inhibitor, increases cAMP and cGMP by preventing their degradation, enhancing PKA and PKG activity, which can lead to EF-CAB5 activation. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Increases intracellular calcium concentration, activating calmodulin-dependent kinases that can phosphorylate and activate EF-CAB5. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Activates protein kinase C, which can phosphorylate target proteins, possibly including EF-CAB5. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor, affects AKT signaling, leading to alterations in downstream targets that can activate EF-CAB5. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor, affects ERK pathway, with subsequent changes in phosphorylation patterns that can activate EF-CAB5. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $60.00 $270.00 $350.00 | 48 | |
Activates AMPK, which can influence various signaling pathways and may modify EF-CAB5 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAPK, altering the stress response pathway, which can affect the activation state of EF-CAB5. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, changing transcription factor activity, which can lead to the activation of EF-CAB5. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Inhibits protein phosphatases PP1 and PP2A, maintaining proteins in a phosphorylated state, which can promote EF-CAB5 activation. |